ALFRED D KINGSLEY

CIK 1229339 · Chairman · last filed 2023-07-03

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$5.90M

Companies

5

Total Filings

59

Lifetime Open-Market Net

-$3.23M

Filer Profile

Reported Address
150 E 57TH STREET
NEW YORK, NY 10022
Related Filers
Lineage Cell Therapeutics, Inc. — 98 joint filings, latest 2023-07-03
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
LCTX Chairman 5,845,596 $1.01 $5.90M $0 5 2023-07-03
Insight Molecular Diagnostics Inc. (OCX) Delisted Director 25,394 $3.20 $81.3K $7.9K 15 2023-06-27
Lineage Cell Therapeutics, Inc. (BTX.WS) Delisted See Remarks 5,846,906 -$3.27M 33 2018-07-03
Asterias Biotherapeutics, Inc. (AST.WS) Delisted Director 9,000 $11.7K 1 2016-06-10
Asterias Biotherapeutics, Inc. (AST) Delisted Director 5,000 $21.6K 3 2016-03-01

Recent Filings · Page 6 of 6

59 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2009-08-24 Lineage Cell Therapeutics, Inc. (BTX.WS) Delisted Mixed +317,913 $0 EDGAR
2009-07-06 Lineage Cell Therapeutics, Inc. (BTX.WS) Delisted Grant (A) $0 EDGAR
2009-04-20 Lineage Cell Therapeutics, Inc. (BTX.WS) Delisted Other (J) +21,716 $0 EDGAR
2009-04-16 Lineage Cell Therapeutics, Inc. (BTX.WS) Delisted Other (J) −191,163 $0 EDGAR
2009-01-08 Lineage Cell Therapeutics, Inc. (BTX.WS) Delisted Other (J) −248,082 $0 EDGAR
2008-11-20 Lineage Cell Therapeutics, Inc. (BTX.WS) Delisted Other (J) +79,076 $0 EDGAR
2008-04-16 Lineage Cell Therapeutics, Inc. (BTX.WS) Delisted Other (J) +410,000 $0 EDGAR
2007-10-23 Lineage Cell Therapeutics, Inc. (BTX.WS) Delisted Other (J) +50,000 $0 EDGAR
2007-05-08 Lineage Cell Therapeutics, Inc. (BTX.WS) Delisted Other (J) +110,000 $0 EDGAR
Showing 5159 of 59
Page 6 of 6
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.